“At Arisaph, we understand that we have a responsibility to develop differentiated therapies to alleviate the hardships patients endure and we are dedicated toward the goal of developing value added therapies.”
– Dr. William Bachovchin, Co-Founder, EVP and Chief Scientific Officer
Specificity Profiling
Specificity profiling is a proprietary drug discovery platform that can be broadly applied to modulate numerous proteases. By using the specificity profiling platform, Arisaph is able to expedite the drug design-and-discovery process for many potential compounds. The technique allows for rapid screening of the best inhibitors within a library of potential inhibitors. This technique was successfully reduced to practice in design ing Arisaph's potent and selective DPP IV inhibitors and stable GLP-1 analogs for the treatment of Type II diabetes.Division of Schering-Plough until 1995, last serving as its President.
Ultra-Smart Pro-Drugs
The ultra-smart drug discovery platform leverages the in-depth understanding of enzyme substrate complexes in order to produce pro-drugs that act selectively and temporally on specific targets. The platform is applied to create compounds that are inactive en route to the target, hyperactive at target site, and inactive again while diffusing away. The discovery platform is extremely useful in developing targeted therapies for cancer, in which the cytotoxicity of the ultra-smart pro-drug can be turned on and off. Arisaph has demonstrated proof-of-concept of the platform in the design and synthesis of FAP-activated ultra-smart pro-drug candidates, which are currently being evaluated for the treatment of solid tumors.
PEP (Peptide Enhancing Platform) Drug Discovery
The PEP drug discovery platform is a technique that can be selectively applied, in vivo, to render biologically active peptides stable to serine protease degradation. This action effectively increases both the potency and the duration of action. Arisaph has successfully reduced to practice the PEP discovery technique in the development of reverse D-4, a novel apo A-I mimetic peptide that showed significant regression of atherosclerosis in preclinical animal studies. Reverse D-4F has shown promising results in reducing atherosclerosis and is currently being developed as a therapy to treat heart disease, the number one cause of death in the United States.1
